Brainomix
Brainomix is a UK-based AI medical imaging company developing FDA-cleared imaging biomarkers for stroke, lung fibrosis, and cancer. Founded in 2010 as a University of Oxford spinout, it serves hospitals, healthcare systems, and pharmaceutical companies across 30+ countries.
- Company typePrivate
- Founded2010
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Brainomix does
Brainomix is a UK-based medical imaging software company founded in 2010 as a spinout from the University of Oxford. It develops AI-powered imaging biomarkers that automate the interpretation of CT, CTA, CTP, and MRI brain and lung scans, with a primary focus on acute stroke assessment and an expanding portfolio in pulmonary fibrosis and oncology. The company's flagship platform, Brainomix 360 Stroke, integrates modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) that score ASPECTS, detect large vessel occlusions, quantify perfusion cores and penumbra, and deliver real-time smartphone alerts to clinicians. The platform is FDA-cleared and CE-marked as a Class IIa medical device, and the company has also received FDA clearance for its e-Lung module targeting progressive pulmonary fibrosis and has begun positioning Brainomix 360 Cancer for solid tumor assessment.
The company generates revenue through enterprise software licensing to hospitals and healthcare systems on multi-year subscription contracts, complemented by professional services for clinical trial imaging analysis supplied to pharmaceutical sponsors. Pricing is quote-based with modules sold individually or bundled. Distribution combines a direct enterprise sales force (with dedicated Sales Directors for EMEA and US regions) and channel partnerships with major neurovascular device companies including Medtronic, Stryker Neurovascular, 3DR Labs, Blackford, and Calantic Digital Solutions. Reported scale metrics include deployments across 30+ countries, 100+ NHS hospitals in England, 2 million+ cumulative scans processed, a scan rate of one patient every three minutes, and 56+ peer-reviewed clinical publications, including the largest real-world stroke AI evaluation (450,000+ patients across 107 hospitals) published in The Lancet Digital Health.
Brainomix firmographics
Firmographics- Name
- Brainomix
- Legal name
- Brainomix Limited
- Website
- https://brainomix.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Brainomix is a UK-based AI medical imaging company developing FDA-cleared imaging biomarkers for stroke, lung fibrosis, and cancer. Founded in 2010 as a University of Oxford spinout, it serves hospitals, healthcare systems, and pharmaceutical companies across 30+ countries.
- Ownership category
- akta.pro rank
Brainomix industry classification
Industry- Product category
- AI Medical Imaging Software
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Brainomix is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Brainomix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Healthcare Software Licensing: Brainomix 360 Stroke and e-Lung platforms licensed to hospitals as medical devices with modules (e-ASPECTS, e-CTA, e-CTP) available separately or as integrated packages. Licensed as CE-marked Class IIa medical devices for clinical decision support.
- Clinical Trial Imaging Services: Quantitative imaging biomarker analysis and Core Lab analytics services for pharmaceutical clinical trials. Supports patient selection, endpoint assessment, and retrospective analysis for stroke, lung fibrosis, and oncology studies.
- Professional Services & Training: Implementation, training, and customer support services with 24/7 SLA support, on-site training, and customization services for hospital integration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise hospital licensing with modular options |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Brainomix product offering
Product offeringCore offering
Brainomix develops and sells AI-powered medical imaging software (the Brainomix 360 platform) that automates analysis of CT, CTA, CTP, and MRI scans for acute stroke assessment, pulmonary fibrosis detection, and solid tumor evaluation. The software is licensed to hospitals and healthcare systems as CE-marked Class IIa and FDA-cleared medical devices, with separate modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) available individually or as integrated packages. The company also provides clinical trial imaging biomarker services and Core Lab analytics to pharmaceutical companies for drug development.
Product overview
Brainomix offers the Brainomix 360 platform, a comprehensive AI-powered imaging solution with multiple integrated modules. The platform comprises Brainomix 360 Stroke (the core stroke imaging platform) with add-on modules including e-ASPECTS for NCCT analysis, e-CTA for CTA/LVO detection, e-CTP for perfusion analysis, e-MRI for advanced MRI assessment, Triage Stroke for ICH notification, and Triage LVO for LVO alerts. The platform also extends to e-Lung for pulmonary fibrosis CT analysis and Brainomix 360 Cancer for tumor assessment in clinical trials. Results are delivered via PACS integration, email notifications, mobile apps (iOS/Android), and web browser interface.
Differentiator
Problem solved
Functional benefit
Brands
- Brainomix 360 Stroke: Comprehensive AI-powered stroke imaging platform providing decision support for acute stroke assessment, including e-ASPECTS, e-CTA, e-CTP, e-MRI modules.
- e-Lung
- Brainomix 360 Cancer
- e-ASPECTS
- e-CTA
- e-CTP
- e-MRI
- Triage Stroke
- Triage LVO
Products and services
- Brainomix 360 Stroke Comprehensive FDA-cleared and CE-marked AI imaging platform for acute stroke assessment, supporting automated analysis of non-contrast CT, CTA, CTP, and MRI images across the full stroke pathway from diagnosis to treatment decisions. Includes modules for ASPECTS scoring (e-ASPECTS), LVO detection (e-CTA), perfusion analysis (e-CTP), MRI analysis (e-MRI), and real-time triage notifications (Triage Stroke, Triage LVO). Licensed to hospitals and healthcare systems as CE-marked Class IIa medical devices.
- e-Lung FDA-cleared AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans to detect progressive pulmonary fibrosis (PPF). Enables clinicians to identify subtle deteriorations over multiple scan timepoints, supporting earlier diagnosis and treatment decisions for pulmonary fibrosis patients. Deployed through partnership with Boehringer Ingelheim.
- Brainomix 360 Cancer AI-powered solution for assessment of solid tumors, characterizing and quantifying tumors using imaging biomarkers. Available for use in clinical trials to support efficacy detection and Blinded Independent Central Review (BICR). Developed in collaboration with pharma partners for oncology drug development.
- Life Sciences Imaging Biomarker Services AI-powered quantitative imaging biomarkers and regulated software services for pharmaceutical and biotech clinical trials. Includes retrospective analysis, prospective trial support, real-world validation, and bespoke digital biomarker development. Supports patient selection, endpoint assessment, and efficacy detection for pharma sponsors across stroke, pulmonary fibrosis, and oncology indications. Provided through direct engagement with pharma companies and CRO partnerships.
Quantifiable outcome
- 100% relative increase in mechanical thrombectomy rates across NHS hospitals in England using Brainomix 360 Stroke
- +5 more outcomes
Companies that use Brainomix
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles2 records
Brainomix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability3 records
Feature9 records
Brainomix partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered flagship, core and minor.
- Boehringer IngelheimflagshipExpanded strategic partnership to advance clinical deployment of e-Lung, FDA-cleared AI-powered imaging platform for detecting progressive pulmonary fibrosis. Next phase PROGRESS-PPF is a prospective multicenter study across US sites generating real-world evidence. Prior REVISE-PPF retrospective study demonstrated e-Lung could identify PPF up to 28 months earlier than clinical diagnoses. Also collaborated on INBUILD Phase III trial validation.
- Argenica TherapeuticscorePartnership to analyze Phase II clinical trial data for ARG-007 neuroprotective drug for acute ischemic stroke. Brainomix AI-powered imaging analysis confirmed statistically significant efficacy in patients with large strokes, demonstrating improved neurological outcomes and smaller infarct volumes.
- 3DR LabscoreStrategic partnership to support acute stroke care in US through clinically validated and FDA-cleared Brainomix 360 Stroke imaging solution. 3DR Labs is market leader in medical imaging post-processing services.
- CSLcoreInternational research collaboration validating significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke. Published in Frontiers in Neurology.
- MedtronicflagshipCollaboration between leading stroke AI imaging partner and leading neurovascular device provider to enhance stroke care, expand access to life-changing treatments, and improve patient outcomes.
- Nanoflex RoboticscoreAI-assisted robotic system development for remote stroke intervention. Swiss-based Nanoflex received Innosuisse grant with Brainomix as UK collaborator for AI-powered remote diagnosis and treatment platform starting 2024. Project aims to develop AI-assisted magnetic navigation system for robotic surgical tools.
- AstraZenecacorePartnership to analyze Phase 2 tralokinumab clinical trial data using Brainomix AI-powered software and biomarkers to uncover novel insights in interstitial lung disease. Published in AJRCCM.
- Bridge BiotherapeuticsminorPartnership on BBT-877 (NCT05483907) study assessing treatment effect in IPF. Brainomix technology and AI imaging biomarkers providing deep data analytics to enrich clinical development.
- PixylminorExclusive distribution partnership for Pixyl.Neuro.MS Software as a Service solution in UK, Ireland, Nordics, and key Eastern Europe markets for multiple sclerosis imaging.
- Stryker NeurovascularcorePartnership to expand access to life-saving stroke treatments by combining Stryker's neurovascular devices with Brainomix AI imaging for improved stroke network care.
- BlackfordminorAI partnership for stroke care increasing access to advanced AI-assisted stroke care through Blackford's platform distribution.
- OSIC (Open Source Imaging Consortium)minorFounder member of consortium connecting academia, industry, and philanthropy in fight against lung disease. Collaborating on e-ILD platform development.
- NCIMI (National Consortium of Intelligent Medical Imaging)minorUK government-funded collaboration evaluating AI-powered technology in lung cancer care. Brainomix e-ACT for automated assessment of disease progression and treatment response.
- Angels InitiativeflagshipProud partner alongside WSO and ESO. Initiative built global community of 5,000+ hospitals to increase patients treated in stroke ready hospitals and optimize treatment quality.
- TIPAL TrialminorCollaboration assessing Brainomix novel IPF biomarker in lung disease. e-Lung CT scanning technology integrated into TIPAL study for interstitial lung abnormalities.
- Wallaby MedicalminorChannel partnership for distribution of stroke AI solutions in target markets.
- Calantic Digital SolutionsminorDistribution partnership for AI imaging solutions in digital health markets.
- OxLEPminorOxford-based local enterprise partnership supporting innovation and growth in Oxford region.
- ForaminorChannel partnership for stroke AI solution distribution.
- Acticor BiotechminorPost-hoc assessment of ACTIMIS study results using Brainomix AI software to reinforce glenzocimab's mode of action in stroke patients.
- LumosaminorLife sciences partnership for stroke therapy clinical development.
- Remedy PartnersminorLife sciences partnership for AI-enhanced clinical trial solutions.
Scale indicators12 records
Recent moves10 records
Expansion highlights7 records
Brainomix competitors and assessment
Company assessmentDirect peers
- RapidAI: Direct competitor selling FDA-cleared AI modules for ASPECTS scoring, CT perfusion, and LVO detection, with deep US hospital penetration — the closest direct peer to Brainomix 360 Stroke.
- Viz.ai: Direct competitor focused on LVO/ICH triage and care coordination, also expanding into cardiology and other specialties; competes head-to-head in US stroke networks for AI imaging and workflow.
- Avicenna.AI: Direct peer offering AI tools for stroke and broader CT triage, with FDA-cleared modules for LVO, ICH, and PE — overlapping product footprint and similar hospital GTM.
- Nico.lab: Europe-based direct peer with StrokeViewer, a CE-marked AI suite for ASPECTS, LVO, and perfusion analysis; comparable in stroke-only focus and European hospital customer base.
- Ischemaview: Direct peer providing RAPID software for CT/MR perfusion and ASPECTS used widely in stroke trials and clinical practice; significant overlap with Brainomix's clinical-trial imaging services and stroke modules.
Emerging players
- Aidoc: Broader AI imaging vendor with FDA-cleared triage across multiple body parts; partial overlap via ICH/LVO detection and competes for the same radiology AI budget, though its portfolio is wider than stroke.
- Qure.ai: AI imaging company with FDA/CE-cleared modules for head CT (ICH, stroke, midline shift) and chest X-ray/tuberculosis; comparable in head CT triage and emerging-market deployment model.
- icometrix: Brain MRI AI vendor with FDA-cleared and CE-marked modules for multiple sclerosis and dementia; adjacent neuro-imaging focus with similar clinical evidence-based GTM and pharma services motion.
- Riverain Technologies: AI vendor specializing in chest CT and X-ray, including ClearRead CT for lung nodule and fibrosis detection; overlaps with Brainomix e-Lung in lung imaging AI.
Broad incumbents
- Nanox: Broad medical imaging and AI platform (incorporating Zebra Medical Vision assets) selling multi-disease AI algorithms including stroke and lung; broader and less specialized than Brainomix but addresses the same hospital customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Brainomix social profiles
Digital presenceBrainomix compliance and trust
Trust signalCompliance3 records
Brainomix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brainomix leadership team
Management profileNumber of profiles
Profiles17 records
Brainomix subsidiaries and ownership
Company hierarchySubsidiaries1 record
Brainomix funding detail
Funding detailFunding overview
Funding rounds9 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brainomix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brainomix
What does Brainomix do?
Brainomix develops and sells AI-powered medical imaging software (the Brainomix 360 platform) that automates analysis of CT, CTA, CTP, and MRI scans for acute stroke assessment, pulmonary fibrosis detection, and solid tumor evaluation. The software is licensed to hospitals and healthcare systems as CE-marked Class IIa and FDA-cleared medical devices, with separate modules (e-ASPECTS, e-CTA, e-CTP, e-MRI, Triage Stroke, Triage LVO) available individually or as integrated packages. The company also provides clinical trial imaging biomarker services and Core Lab analytics to pharmaceutical companies for drug development.
Is Brainomix a public or private company?
Brainomix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Brainomix founded?
Brainomix was founded in 2010. It employs 51 to 100 people.
Where is Brainomix based?
Brainomix is headquartered in Oxford, United Kingdom, in the Europe region.
How does Brainomix make money?
Three revenue lines are on record. Healthcare Software Licensing is the primary driver. The others are clinical Trial Imaging Services and professional Services & Training.
Who are Brainomix's main competitors?
Direct peers on record are RapidAI, Viz.ai, Avicenna.AI, Nico.lab and Ischemaview. Emerging players are Aidoc, Qure.ai, icometrix and Riverain Technologies. Nanox is listed as a broad incumbent.
Does Brainomix have an API?
No public API is recorded for Brainomix.
What industry is Brainomix in?
Brainomix's product category is AI Medical Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 54169 and its SIC code is 7372.